JMIR Publications today announced the release of timely new articles in its News and Outlook section showcasing the transformative potential of precision oncology. The article “Further Promise and Potential of Precision Medicine in Oncology” details how moving from a “one size fits all” approach to individualized multidrug therapy can significantly improve outcomes for patients with aggressive advanced cancers.
This report, written by JMIR correspondent Shalini Katuria Narang, highlights JMIR’s latest findings. Examining profile-related evidence to determine personalized cancer treatment (I-prediction) Trial. The study found that patients had better treatment responses, longer progression-free survival, and longer overall survival when drug therapy was closely matched to patients’ specific tumor mutations.
Breaking the “one mutation, one drug” paradigm
Traditional precision medicine often focuses on targeting a single genetic mutation with a single drug. But the I-PREDICT trial, led by researchers at the University of California, San Diego School of Medicine, confirmed that advanced tumors are much more complex.
The analysis revealed several breakthrough insights.
-
“N-of-1” strategy: By using advanced genomic sequencing to create unique tumor profiles, clinicians developed 103 distinct combinations of FDA-approved drugs to target multiple pathways simultaneously, but there was little prior established safety data for these specific combinations.
-
Excellent safety profile: Despite using a complex drug “cocktail,” only 6.5% of patients experienced severe drug-related toxicity, compared with 15.5% of patients who received established standardized regimens.
-
Precision matters: Approximately 95% of patients in the trial had a unique molecular landscape. The study found a direct correlation, with higher “matching scores” between drugs and tumor changes associated with better survival.
Just as we are all a little different, so is each patient’s tumor. We figure out how to find the best treatment by focusing on the unique biology of each patient and their tumor. ”
Dr. Jason Schicklic, senior author of this study and professor at the University of California, San Diego School of Medicine
The future of standard care
This article highlights that while further randomized validation is needed, the era of precision cocktails is rapidly approaching. With faster molecular tests and an expanding repertoire of targeted drugs, researchers hope that this personalized approach will soon become an additional standard option for all cancer patients.
“I hope that in 10 years, personalized cancer medicine will be one of the standard approaches,” added Dr. Shuaki Kato, a medical oncologist at the University of California, San Diego. “Compared to chemotherapy, more precisely targeted therapies are much less invasive for patients.”
sauce:
Reference magazines:
Naran, South Carolina (2026). Further promise and potential of precision medicine in oncology. Medical Internet Research Journal. DOI: 10.2196/95657. https://www.jmir.org/2026/1/e95657
